60 Degrees Pharmaceuticals LLC
60 Degrees Pharmaceuticals is a leading company in the development and commercialization of medicines for infectious diseases, including tropical diseases such as malaria, dengue, babesiosis, and fungal infections. Founded in 2010, the company focuses on innovative therapies to treat and prevent infectious diseases, aiming to improve and extend people's lives worldwide. With a mission to address critical research gaps, the company collaborates with research institutions and has a strong pipeline of clinical programs, including the FDA-approved ARAKODA® (tafenoquine) for malaria prevention and ongoing research into treatments for babesiosis, fungal diseases, and dengue fever. The company is committed to serving the global health community through its research, development, and commercial efforts.
Industries
Nr. of Employees
small (1-50)
60 Degrees Pharmaceuticals LLC
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036
Products
Oral tafenoquine tablets (8‑aminoquinoline) — malaria prophylaxis
An 8‑aminoquinoline antimalarial formulation approved by the U.S. FDA for malaria prevention and launched commercially in the U.S. in 2019.
Celgosivir (host-targeted glucosidase inhibitor) — development candidate
A host-targeted glucosidase inhibitor under clinical development for dengue and being evaluated for activity against respiratory viruses in preclinical and early clinical studies; prior Phase IB/Phase I data reported.
Oral tafenoquine tablets (8‑aminoquinoline) — malaria prophylaxis
An 8‑aminoquinoline antimalarial formulation approved by the U.S. FDA for malaria prevention and launched commercially in the U.S. in 2019.
Celgosivir (host-targeted glucosidase inhibitor) — development candidate
A host-targeted glucosidase inhibitor under clinical development for dengue and being evaluated for activity against respiratory viruses in preclinical and early clinical studies; prior Phase IB/Phase I data reported.
Services
Sponsor-led design and execution of clinical studies across Phase I–III for infectious disease indications.
Execution of cell-culture antiviral/antifungal assays and animal-model efficacy and safety studies.
Preparation of regulatory filings, engagement with regulatory agencies, and management of post-approval commitments.
Planning and execution of product launch activities, prescribing information preparation, and targeted marketing.
Negotiation and management of licensing agreements and collaborative research partnerships with academic and government organizations.
Adverse event reporting systems, long-term safety studies and monitoring for marketed products.
Sponsor-led design and execution of clinical studies across Phase I–III for infectious disease indications.
Execution of cell-culture antiviral/antifungal assays and animal-model efficacy and safety studies.
Preparation of regulatory filings, engagement with regulatory agencies, and management of post-approval commitments.
Planning and execution of product launch activities, prescribing information preparation, and targeted marketing.
Negotiation and management of licensing agreements and collaborative research partnerships with academic and government organizations.
Adverse event reporting systems, long-term safety studies and monitoring for marketed products.
Expertise Areas
- Clinical trial management
- Infectious disease therapeutics development
- Drug repurposing and repositioning
- Non-clinical pharmacology and toxicology
Key Technologies
- In vitro cell-culture assays
- Animal models for efficacy and safety
- Host-targeted small-molecule therapeutics
- Clinical trial protocol design and endpoint development
News & Updates
Discussion of future plans for testing of ARAKODA® (tafenoquine) for potential use in COVID-19, including recent in vitro study results.
Participation as a presenter and partner at the European Life Sciences CEO Forum in Zurich, March 6-7, 2017.
Participation in the AusBiotech Series in March 2017.
Participation as a presenting and partnering company at International Bio, June 19-22, 2017.
The company received a U.S. patent for tafenoquine for COVID-19 and lung infections, announced on April 26, 2023.
Published by New Microbes and New Infections on June 21, 2022, indicating promising results for ARAKODA® in COVID-19.
Discussion of future plans for testing of ARAKODA® (tafenoquine) for potential use in COVID-19, including recent in vitro study results.
Participation as a presenter and partner at the European Life Sciences CEO Forum in Zurich, March 6-7, 2017.
Participation in the AusBiotech Series in March 2017.
Participation as a presenting and partnering company at International Bio, June 19-22, 2017.
The company received a U.S. patent for tafenoquine for COVID-19 and lung infections, announced on April 26, 2023.
Published by New Microbes and New Infections on June 21, 2022, indicating promising results for ARAKODA® in COVID-19.